Qianben Wang, Ph.D., Doctoral Supervisor, Tenured Professor, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences / School of Basic Medicine, Peking Union Medical College. He received his Ph.D. from the University of Maryland, Baltimore in 2002 and conducted postdoctoral research at the Dana-Farber Cancer Institute, Harvard Medical School from 2003 to 2008, where he also served as an Instructor. He subsequently held faculty positions at The Ohio State University College of Medicine, serving as Assistant Professor (tenure-track) in the Department of Molecular and Cellular Biochemistry, Associate Professor (tenured) in the Departments of Molecular and Cellular Biochemistry as well as Cancer Biology and Genetics, and later as a tenured Professor and Endowed Chair in the Department of Pathology at Duke University School of Medicine. In August 2025, he returned to China full-time to join the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, and the School of Basic Medicine, Peking Union Medical College.

    Professor Wang has long focused on gene regulatory mechanisms and RNA-targeted therapeutic strategies in human diseases, making systematic contributions to the transcriptional and epigenetic regulation of hormone-dependent cancers. In recent years, he has integrated CRISPR/Cas13 RNA editing with lipid nanoparticle delivery to establish an “RNA precision therapeutic platform,” achieving advances in addressing cancer metastasis, drug resistance, immune evasion, and lung repair following coronavirus infection. His research has been published in leading international journals including Cell, Molecular Cell, Nature Genetics, Nature Chemical Biology, Cell Research, PNAS, Nature Communications, EMBO Journal, Cancer Research, Advanced Science, and Nano Research.

    He currently serves as a Director at Large and Executive Committee Member of the Society for Basic Urologic Research (SBUR), and Chair of its 33rd Annual Meeting in 2025. He previously served as a standing member of the NIH Gene Regulation in Cancer (GRIC) Study Section and as a member of the Duke University School of Medicine Clinical Sciences Appointments, Promotion, & Tenure Committee. He has led multiple NIH U54 and R01 grants as well as Department of Defense (DoD) research projects.